Get the Stockscreener App
23.39
2.86%
0.65
After Hours:
23.39
Amphastar Pharmaceuticals Inc stock is traded at $23.39, with a volume of 366.93K.
It is up +2.86% in the last 24 hours and up +14.38% over the past month.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
See More
Previous Close:
$22.74
Open:
$22.85
24h Volume:
366.93K
Relative Volume:
0.72
Market Cap:
$1.04B
Revenue:
$719.89M
Net Income/Loss:
$98.09M
P/E Ratio:
11.50
EPS:
2.0334
Net Cash Flow:
$118.98M
1W Performance:
+7.20%
1M Performance:
+14.38%
6M Performance:
-7.59%
1Y Performance:
-6.89%
1-Day Range:
$22.75
$23.46
1-Week Range:
$21.48
$23.46
52-Week Range:
$17.03
$31.26
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
23.39 | 1.01B | 719.89M | 98.09M | 118.98M | 2.0334 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Aug-12-25 | Upgrade | Needham | Hold → Buy |
| May-12-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-04-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-22-24 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Nov-17-23 | Initiated | BofA Securities | Neutral |
| Jul-25-23 | Resumed | Jefferies | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jul-29-22 | Initiated | CapitalOne | Overweight |
| Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-01-20 | Initiated | Northland Capital | Outperform |
| Mar-13-19 | Downgrade | Needham | Buy → Hold |
| Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-10-18 | Reiterated | Needham | Buy |
| Mar-13-18 | Reiterated | Needham | Buy |
| Dec-01-17 | Reiterated | Needham | Buy |
| Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-27-17 | Reiterated | Needham | Buy |
| Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-09-16 | Reiterated | Needham | Buy |
| May-10-16 | Reiterated | Needham | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| Jun-19-15 | Reiterated | Needham | Buy |
| Jun-03-15 | Initiated | Raymond James | Strong Buy |
| Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
MSN Money - MSN
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Amphastar Pharmaceuticals Faces Downgrade Despite Strong Annual Revenue - HarianBasis.co
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026 - Black Hills Pioneer
Jefferies Downgrades Amphastar Pharmaceuticals (AMPH), Cites Lack of Meaningful Upside Catalysts - Insider Monkey
Amphastar: A Cheap Multiple Doing Exactly What It's Supposed To Do (NASDAQ:AMPH) - Seeking Alpha
After-close Q1 results: Amphastar schedules May 7 investor call - Stock Titan
Are investors undervaluing Amphastar Pharmaceuticals (AMPH) right now? - MSN
Amphastar outlines key launches and product growth drivers for 2025 - MSN
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance Australia
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now? - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) to Release Earnings on Wednesday - MarketBeat
Do options traders know something about Amphastar Pharmaceuticals stock we don't? - MSN
AMPH Price Today: Amphastar Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Amphastar reports FDA approval for teriparatide injection - MSN
Boston Trust Walden Corp Reduces Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals Downgrade: Stock Falls After Analyst MoveNews and Statistics - IndexBox
Jefferies downgrades Amphastar Pharmaceuticals (AMPH) - MSN
Why Amphastar Pharmaceuticals (AMPH) Shares Are Sliding Today - Yahoo Finance
Amphastar Pharmaceuticals (AMPH): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Down 7.4%Time to Sell? - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Earns Hold Rating from Jefferies Financial Group - MarketBeat
Why (AMPH) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Amphastar (AMPH) Stock Market Order (Bullish Sentiment) 2026-04-18Retail Trader Ideas - Xã Thanh Hà
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know - Yahoo Finance
More Than 81,000 Critical Allergy Medications Recalled Nationwide - The Healthy @Reader's Digest
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Amphastar Pharmaceuticals Highlights Baqsimi Milestones, Primatene Growth at Needham Conference - MarketBeat
AMPH: Baqsimi and Primatene Mist drive growth, with new launches and disciplined BD fueling expansion - TradingView
Amphastar Pharmaceuticals, Inc. ($AMPH) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Amphastar Pharmaceuticals, Inc. SEC Filing - Stock Titan
Amphastar (NASDAQ: AMPH) outlines 2026 virtual meeting, director and pay votes - Stock Titan
Amphastar Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
How The Story Is Shifting For Amphastar Pharmaceuticals (AMPH) After Guidance Cut And New Launches - Yahoo Finance
AMPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Barclays Lowers Price Target for Amphastar Pharma (AMPH) | AMPH Stock News - GuruFocus
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Lowered to $23.00 at Barclays - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Average Rating of "Hold" by Brokerages - MarketBeat
Understanding Momentum Shifts in (AMPH) - Stock Traders Daily
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference - ACCESS Newswire
Amphastar CFO, regulatory chief to present April 14; replay lasts 30 days - Stock Titan
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):